U.S. Cell Banking Outsourcing Market Size Report, 2024-2033
The U.S. cell banking outsourcing market size was estimated at USD 5.26 billion in 2023 and is projected to hit around USD 20.89 billion by 2033, growing at a CAGR of 14.79% during the forecast period from 2024 to 2033.
Key Takeaways:
U.S. Cell Banking Outsourcing Market Growth
The driving factors for this growth include the rising cryopreservation & cell bank preparation methodologies, and escalating demand for monoclonal antibodies. Moreover, increasing R&D activities in this sector is likely to impact significantly over the forecast period.
The U.S. cell banking outsourcing market accounted for a 42% share of the global cell banking outsourcing market in 2023. The demand for cell banking is increasing due to the rise of cell therapies. Furthermore, the COVID-19 pandemic has had a significant impact on companies engaged in manufacturing MSC products from donated birth tissues, potentially leading to market growth post-pandemic. Additionally, funding and various initiatives are crucial in advancing stable cell lines and implementing new technologies for cell line storage and characterization, expediting market growth.
The market's growth has been driven by various factors, including the increasing production of vaccines, growing prevalence of cancer, rising number of cell banks, and escalating demand for monoclonal antibodies. These trends reflect a significant expansion in the industry, highlighting the importance of cell banking outsourcing services in supporting research and development activities across different sectors.
Moreover, outsourcing providers offer expertise and cutting-edge facilities, enabling access to state-of-the-art technologies that fulfill the demand for cell banking. Additionally, cell banking outsourcing aids in cost optimization by eliminating the necessity for internal infrastructure and resources, Thus, these factors drive growth and expansion of the cell banking outsourcing market.
U.S. Cell Banking Outsourcing Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 6.04 Billion |
| Market Size by 2033 | USD 20.89 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 14.79% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Type, cell type, phase |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Cryo-Cell International, Inc; Charles River Laboratories; Covance; GlobalStem Inc.; BioReliance; Sigma-Aldrich Co. LLC; Stem Cyte, Inc; ViaCord; Cord Blood Registry;SmartCells, Inc.; Cryo Stemcell |
Segments Insights:
Type Insights
Based on type, master cell banking dominated the market with a share of 64.9% in 2023 owing to its need for manufacturing and usage in working cell banks. Master cell banks are considered the primary source of cells that perform cell storage to maintain their viability. Moreover, the growing number of autoimmune diseases and cancer therapeutic approaches further boost the segment’s growth.
Working cell banking is projected to expand at the fastest CAGR from 2024 to 2033. Working cell banks serve as specialized repositories. They provide a continuous supply of renewable and consistent cells to perform research for biological drugs, therapies, and vaccines in biopharmaceutical companies. These applications increases the demand of this segment. This is anticipated to drive the market growth in the forecast period.
Cell Type Insights
Based on cell type, stem cell type held the largest share in 2023 and is expected to witness growth at the fastest CAGR over the forecast period owing to the widespread applicability of stem cells. Moreover, the grants offered by government authorities further elevate R&D activities in the stem cell sector thereby enhancing the demand for stem cells.
Non-cell stem type is anticipated to expand at a significant CAGR from 2024 to 2033. The non-stem includes somatic cells. These cells are further used in therapeutics for disease modeling, regenerative medicine, and drug discovery. These applications are anticipated to drive market growth over the forecast period.
Phase Insights
Based on phase, bank storage dominated the market with a share of 44.11% in 2023 due to the growing need for preservation techniques to support long-term storage of biological materials. Moreover, advanced cryopreservation methods are expected to fuel the segment’s growth over the forecast period.
Bank characterization& testing is projected to grow at the largest CAGR from 2024 to 2033. The outsourcing services of bank characterization & testing allow companies to access specialized services and capabilities, enhancing their ability to meet regulatory requirements and advance their research and development efforts in the field of cell therapy. For instance, Charles River Laboratories offers cell characterization and biosafety testing for MCBs, WCBs, and EoPCB or cells at the limit (CAL) of in vitro cell age used for production.
Recent Developments
Some of the prominent players in the U.S. Cell Banking Outsourcing Market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Cell Banking Outsourcing market.
By Type
By Cell Type
By Phase
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Cell type
1.2.3. Phase
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. nova one advisor internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in Italy
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type
2.2.2. Cell type
2.2.3. Phase
2.3. Competitive Insights
Chapter 3. Cell Banking Outsourcing Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.3. Market Driver Analysis
3.4. Market Restraint Analysis
3.4.1. Industry Analysis - Porter’s Five Forces
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. U.S. Cell Banking Outsourcing Market Type Estimates & Trend Analysis
4.1. U.S. Cell Banking Outsourcing Market Type Dashboard
4.2. U.S. Cell Banking Outsourcing Market Type Movement Analysis
4.3. U.S. Cell Banking Outsourcing Market Size & Forecasts and Trend Analyses, 2021 - 2033
4.4. Master Cell Banking
4.4.1. Master Cell Banking Market, 2021 - 2033
4.5. Working Cell Banking
4.5.1. Working Cell Banking Market, 2021 - 2033
4.6. Viral Cell Banking
4.6.1. Viral Cell Banking Market, 2021 - 2033
Chapter 5. U.S. Cell Banking Outsourcing Market: Cell Type Estimates & Trend Analysis
5.1. U.S. Cell Banking Outsourcing Market Cell Type Dashboard
5.2. U.S. Cell Banking Outsourcing Market Cell Type Movement Analysis
5.3. U.S. Cell Banking Outsourcing Market Size & Forecasts and Trend Analyses, 2021 - 2033
5.4. Stem Cell
5.4.1. Stem Cell Market, 2021 - 2033
5.5. Cord Cell Banking
5.5.1. Cord Cell Banking Market, 2021 - 2033
5.6. Embryonic Stem Cell Banking
5.6.1. Embryonic Stem Cell Banking Market, 2021 - 2033
5.7. Adult Stem Cell Banking
5.7.1. Adult Stem Cell Banking Market, 2021 - 2033
5.8. Dental Stem Cell Banking
5.8.1. Dental Stem Cell Banking Market, 2021 - 2033
5.9. IPS Stem Cell Banking
5.9.1. IPS Stem Cell Banking Market, 2018 - 2030 (USD
5.10. Non-Stem Cell Banking
5.10.1. Non-Stem Cell Market, 2021 - 2033
Chapter 6. U.S.Cell Banking Outsourcing Market: Phase Outlook Estimates & Trend Analysis
6.1. U.S. Cell Banking Outsourcing Phase Model Dashboard
6.2. U.S. Cell Banking Outsourcing Market Phase Movement Analysis
6.3. Cell Banking Outsourcing: Business Model Outlook Movement Analysis
6.3.1. Bank Storage Market, 2021 - 2033
6.3.2. Master Cell Bank Preparation
6.3.2.1. Master Cell Bank Preparation Market, 2021 - 2033
6.3.3. Working Cell Bank Preparation
6.3.3.1. Working Cell Bank Preparation Market, 2021 - 2033
6.3.4. Cell Storage Stability Testing
6.3.4.1. Cell Storage Stability Testing Market, 2021 - 2033
6.3.5. Bank Characterization & Testing
6.3.5.1. Bank Characterization & Testing Market, 2021 - 2033
6.3.6. Safety Testing
6.3.6.1. Safety Testing Market, 2021 - 2033
6.3.7. Viral Cell Banks
6.3.7.1. Viral Cell Banks Market, 2021 - 2033
6.3.8. Microbial Cell Banks
6.3.8.1. Microbial Cell Banks Market, 2021 - 2033
6.3.9. Gene Expression Testing
6.3.9.1. Gene Expression Testing Market, 2021 - 2033
6.3.10. Karyology Testing
6.3.10.1. Karyology Testing Market, 2021 - 2033
6.3.11. Gene Sequencing Testing
6.3.11.1. Gene Sequencing Testing Market, 2021 - 2033
6.3.12. Bank Preparation
6.3.12.1. Bank Preparation Market, 2021 - 2033
6.3.13. Master Cell Bank Preparation
6.3.13.1. Master Cell Bank Preparation Market, 2021 - 2033
6.3.14. Working Cell Bank Preparation
6.3.14.1. Working Cell Bank Preparation Market, 2021 - 2033
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2023
7.3.4. Cerner Corporation
7.3.5. Aldevron
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Charles River Laboratories
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Akron Biotech
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. VGXI, Inc
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Catalent, Inc
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. DH Life Sciences, LLC
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Recipharm AB
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. TriLink BioTechnologies
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. AGC BiologicsL
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives
7.3.14. Thermo Fisher
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Product benchmarking
7.3.14.4. Strategic initiatives
7.3.15. Scientific Inc.
7.3.15.1. Company overview
7.3.15.2. Financial performance
7.3.15.3. Product benchmarking
7.3.15.4. Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers